Depression and Dopamine Transporter Function Study Using C-11 Altropane
NCT01701141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2018-05-21
Summary
Major depressive disorder (MDD) is often characterized by anhedonia and impaired ability to modulate behavior as a function of rewards. However, the neurobiology of anhedonia and reduced reward responsiveness remains largely unknown. Because dopamine (DA) plays a critical role in goal-directed behavior and reinforcement learning, DA dysregulation might play an important role. In fact, several lines of evidence suggest that down-regulation of DA transmission might characterize depression vulnerability and the emergence of depressive symptoms. The current study seeks to elucidate the role of DA dysfunction in MDD. We hypothesize that MDD subjects will show reduced DAT binding potential, reduced reward learning in the probabilistic reward task, and abnormal functional magnetic resonance imaging (fMRI) activation in dorsal and ventral striatal regions during an instrumental learning task.
This study will include three sessions.
The first will take place at Massachusetts General Hospital or at McLean Hospital's Center for Depression, Anxiety and Stress Research. The aims of this session will be to (a) explain the study; (b) collect written informed consent, and (c) assess the subject's eligibility.
Following this, another session (either second or third in order) will take place at the MGH PET Imaging Laboratory. Participants will complete a PET scan and a probabilistic reward task designed to measure reward learning and sensitivity to reward. The radioactive tracer utilized is 11C-altropane.
Another session (either second or third in order) will take place at the McLean Hospital Neuroimaging Center. Participants will complete an instrumental learning task while in the fMRI, followed by a social reinforcement learning task and an implicit learning serial reaction time task upon completion of the scan. In the instrumental learning task, participants have the opportunity to earn money but need to learn, by trial and error, stimulus-outcome associations. The social reinforcement learning task is designed to investigate whether learning deficits in MDD are specific to learning from monetary incentives or whether the learning deficits are more global and are affected when learning from social rewards and punishments. Participants will also complete an implicit learning serial reaction time task, designed to exclude the possibility of global learning deficits in MDD.
Conditions
- Major Depressive Disorder
- Anhedonia
Sponsors & Collaborators
-
Mclean Hospital
lead OTHER
Principal Investigators
-
Diego Pizzagalli, PhD · Mclean Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2014-07-31
- Completion
- 2014-07-31
Countries
- United States
Study Locations
More Related Trials
-
DPA-714 and FDG PET/MRI in Depression
NCT06565936 ·Status: RECRUITING ·Phase: NA
-
Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging
NCT01831440 ·Status: UNKNOWN ·Phase: NA
-
Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave
NCT04456868 ·Status: TERMINATED ·Phase: NA
-
Neuro MRI Biomarkers for Treatment Navigation in Depression
NCT05701267 ·Status: COMPLETED
-
MAO-B Occupancy in Depressed Patients
NCT04841798 ·Status: COMPLETED ·Phase: NA
-
MRI Studies of Emotion in Depression
NCT02429011 ·Status: COMPLETED
-
Multimodal Differences in Effort-based Decision-Making in Depression
NCT06648460 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer
NCT02153281 ·Status: COMPLETED ·Phase: NA
-
The Effects of Sleep Deprivation on Antidepressant Response
NCT00178074 ·Status: COMPLETED ·Phase: PHASE4
-
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
NCT03537794 ·Status: RECRUITING
-
PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder
NCT06452290 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
NCT03761030 ·Status: TERMINATED ·Phase: PHASE4
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
NCT05703685 ·Status: RECRUITING ·Phase: PHASE1
-
Precision Care for Major Depressive Disorder
NCT06580041 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
A Neuroimaging Study of Open-label Placebo in Depressed Adolescents
NCT04201106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation
NCT05909267 ·Status: RECRUITING ·Phase: NA
-
Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial
NCT06626152 ·Status: RECRUITING ·Phase: PHASE2
-
Cerebral Neuroinflammation During Major Depressive Episode
NCT03314155 ·Status: UNKNOWN ·Phase: NA
-
Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study
NCT07247344 ·Status: RECRUITING
-
Antiglucocorticoid Augmentation of antiDepressants in Depression
NCT01375920 ·Status: COMPLETED ·Phase: PHASE3
-
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
NCT01528241 ·Status: COMPLETED ·Phase: PHASE1
-
Using Neuroimaging to Investigate Major Depressive Disorder
NCT00781677 ·Status: COMPLETED
-
A Neurobiological Model of Anhedonia
NCT05629520 ·Status: COMPLETED
-
Functional and Metabolic Changes in the Course of Antidepressive Treatment
NCT02099630 ·Status: COMPLETED
-
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
NCT03148509 ·Status: UNKNOWN ·Phase: PHASE4